



GB 00/08816

PATENTS • DESIGNS  
The  
Patent  
Office  
COPYRIGHT • TRADEMARKS

PCT/GBOO/02216

10/018608



INVESTOR IN PEOPLE

*JH*

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 18 AUG 2000

WIPO

PCP


**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*R. Mahoney*

Dated

4th August 2000

**THIS PAGE BLANK (USPTO)**

22-12-99 14:07

+44 1 80 4702

22-DEC-1999 14:34

FROM HARRISON GODDARD FOOTE

P.04

R-119 Job-893

01633814444


P.04

Patents Form 1/77

**The  
Patent  
Office**

22DEC99 E501172-1 D02973  
P01/7700 0.00-9930252.3

**Request for grant of a patent**



**The Patent Office**  
Cardiff Road  
Newport  
Gwent NP9 1RH

1 Your reference

P15770

2 Patent application number

**9930252.3****22 DEC 1999**

3 Full name, address and postcode of the applicant

**ML Laboratories**  
**17 Hanover Square**  
**LONDON**  
**W1R 9AJ**

Patents ADP number

State of incorporation

**UK**

0715280005

4 Title of the invention

Biologically Active Molecules

5 Name of agent

**HARRISON GODDARD FOOTE**

Address for service

**Belmont House**  
**20 Wood Lane**  
**LEEDS**  
**LS6 2AE**

Patents ADP number

14571001

6 Priority applications

Country

Priority App No

Date of Filing

Patents Form 1/77

Page 1 of 2

Patents Form 1/77

22-12-99 14:07

+44 113 230 4702

22-DEC-1999 14:34

FROM [REDACTED] MERRISON GODDARD FOOTE

P.05

R-119 Job-893

01633814444

P.05

7 Parent application  
(eg Divisional)

Earlier Application No

Date of Filing

8 Statement of Inventorship  
Needed?

yes

9 Number of sheets for any of the following  
(not counting copies of same document)

Continuation sheets of this form

Description

8

Claims

Abstract

Drawings

3

10 Number of other documents attached

Priority documents

Translations of priority documents

P7/77

P9/77

P10/77

Other documents

11 I/We request the grant of a patent on the basis of this application.

Signature

*Harrison G. Goddard Foote*

22 December 1999

12 Name and daytime telephone number of  
person to contact in the United KingdomDr Rob Docherty  
0113 225 8350

22-12-99 14:07

+44 100 30 4702

22-DEC-1999 14:34

FROM MERRISON GODDARD FOOTE

P.06

R-119 Job-893

TO

01633814444

P.06

## BIOLOGICALLY ACTIVE MATERIALS

### **Field of Invention**

5 This invention relates to biologically active materials and, in particular, to materials which comprise a biodegradable polymer linked to a biologically active agent. The invention is concerned with materials known as polymer-drug conjugates which typically contain a therapeutic agent for instance, a bioactive cytotoxic drug, linked to a polymer back-bone. The linkage between the polymer and the drug is typically by  
10 covalent bonding. However, the invention is applicable to other polymer conjugates including those where the biologically active agent is an imaging agent, such as tyrosinamide, a diagnostic agent, or a targeting agent such as biotin.

Reference will be made hereinbelow to polymer-drug conjugates in which the drugs  
15 are anticancer agents. However, the present invention has application in connection with other drugs and/or bioactive agents.

### **Background of the Invention**

20 In designing a polymer-drug conjugate, the aim is to deliver a drug effectively to a therapeutic site such as a tumour. It is known, for instance, that polymer-drugs given intravenously can accumulate selectively in solid tumour tissue by the EPR effect.

The most commonly used anticancer agents are low molecular weight compounds  
25 which readily gain access to cells by rapid passage across the cell membrane. After intravenous (IV) administration, a large percentage of the injected dose leaves the circulation within a few minutes, resulting in a ubiquitous body distribution of drug and little selective concentration in tumour tissue. By creating a macromolecular polymer-anticancer drug conjugate, there is provided an opportunity to improve  
30 tumour specific targeting, to minimise drug entry into sites of toxicity, to control precisely the rate of drug liberation at the target site (giving opportunities for long-

term controlled release) and to deliver the active principal intracellularly, thereby providing a means to overcome p-glycoprotein related multidrug resistance.

Numerous polymers have been proposed for synthesis of polymer-drug conjugates  
5 including polyaminoacids, polysaccharides such as dextran, and synthetic polymers such as N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer. However, these polymers have limitations. For example, a dextran-doxorubicin conjugate has been tested clinically and been found to be much more toxic than the parent drug. Furthermore the HPMA copolymers which have been clinically tested have the  
10 disadvantage of being non-biodegradable in the main chain.

WO-A-98/56424 discloses a polymer-drug conjugate in which the polymer is the polysaccharide dextrin. Such a polymer-drug conjugate may be prepared in various ways. One method involves succinylating dextrin and reacting the succinylated  
15 dextrin with the drug or a reactive derivative thereof.

WO-A-98/56424 includes an example in which the extent of succinylation of dextrin varies from 2.26 to 6.64 Mol%. In a further example the drug doxorubicin is conjugated to succinylated dextrans in which the extent of succinylation varies  
20 from 0.5 to 14.9 Mol%.

WO-A-98/56424 also includes examples showing the rate of degradation of dextrin both in the absence and in the presence of appropriate enzymes and also in rat plasma.  
25

For at least certain applications the rate of degradation of dextrin in a dextrin-drug conjugate is an important consideration. For instance, it may be desirable to have a relatively slow rate of degradation in some applications while in other applications a faster rate of degradation is either acceptable or indeed even preferred.

30

22-12-99 14:07

+44 1 30 4702

22-DEC-1999 14:35

FROM HARRISON GODDARD FOOTE

P.08

R-119 Job-893

TO

01633814444

P.08

### Statement of Invention

It has now been surprisingly discovered that the rate of dextrin degradation is highly dependent on the degree of dextrin backbone substitution. As a result, it is possible 5 to tailor the dextrin by appropriate substitution of its backbone in order to achieve a desired rate of degradation.

More particularly, it has been found that, in the case of substitution of the dextrin backbone by succinoylation, relatively rapid degradation takes place at a degree of 10 succinoylation of up to about 15%. By contrast a degree of succinoylation above 30% very markedly reduces the rate of degradation.

The present invention provides a dextrin-drug conjugate in which the degree of substitution of the dextrin chain is greater than 15%, more preferably greater than 15 20% and most preferably greater than 30%.

The drug of the dextrin-drug conjugate may be loaded on the polymer via a linking group, such as succinoyl, in which case it may be attached to some or all of the linking groups. Alternatively the drug may be directly loaded onto the dextrin 20 backbone in which case the drug itself acts as the substituting group. As a further possibility the drug may be loaded partly via a substituting group and partly directly onto the dextrin backbone.

An embodiment of the invention will now be described by example only and with 25 reference to the following tables and figures;

Table 1 represents the characteristics of different batches of succinylated dextrin doxorubicin conjugates;

30 Table 2 shows the anticancer activity of succinylated dextrin doxorubicin conjugates;

Figure 1 is a graphical representation of the degradation of dextrin, succinylated dextrin and a succinylated dextrin doxorubicin conjugate ( 5% succinylation, 6% doxorubicin);

5 Figure 2 is a graphical representation of the degradation of hyper-succinylated dextrin doxorubicin( 34% succinylation) conjugate with time; and

Figure 3 is a graphical representation of the preferential accumulation of succinylated dextrin doxorubicin conjugate compared to an unconjugated control.

10

#### Detailed description of the invention

##### *Example 1*

15 Dextrin (Mw 51,000 Da) was succinylated using a modification of the method described by Bruneel *et al* (Polymer, 35 (12),(1994), 2656-2658). Doxorubicin was then conjugated directly via an amide bond, conjugated via an N-cis-aconityl spacer or conjugated via a glycyl-N-cis-aconityl spacer.

20 Polymer degradation (unmodified dextrin, succinylated dextrin (5, 15 mol %) and conjugate) was measured in the presence of amylase or lysosomal enzymes to monitor either changes in polymer molecular weight (GPC) or doxorubicin release (HPLC).

25 The dextrin-doxorubicin conjugates had a doxorubicin loading of 6-12 wt% dependent on the reaction conditions used and the degree of succinylation of the dextrin intermediate. Table 1 shows the characteristics of several batches of dextrin-succ-doxorubicin

30

Table 1 Characteristics of batches of dextrin-succ-doxorubicin

Batch No	Dox (wt%)	Free Dox (% total Dox)
1	11.7	0.8
2	11.9	2.0
3	8.7	1.2
4	8.4	0.1

After a 180 min incubation with amylase, unmodified dextrin is almost completely degraded to low molecular products, whilst the succinylated dextrin (5 and 15 mol %) and dextrin-succ-doxorubicin show a biphasic pattern of degradation giving rise to fragments of Mw 4,000, 9,500 and 6,400 Da respectively. Unmodified dextrin had a  $t_{1/2}$  (time for mass to reach half of its original) of 20 min, succinylated dextrin and dextrin-succ-doxorubicin a  $t_{1/2}$  of approximately 15 min.

### *Example 2*

In this example the degradation of dextrans of different degrees of modification was compared. The results are shown in the accompanying drawing. It will be seen that native dextrin is rapidly degraded as are also dextrin with 5% succinylation (whether with or without 6% Dox) and dextrin with 15% succinylation. However, if dextrin is 34% succinylated the degree of degradation is markedly less, there being zero% reduction of the peak mass of primary peak after 60 minutes and only 20% reduction after 180 minutes. In addition, Figure 2 shows that 34% succinylated dextrin doxorubicin conjugate is similarly stable over an extended time course when compared to unconjugated or low level succinylated (5%) controls.

### *Example 3*

In this example increased uptake of 34% succinylated dextrin-doxorubicin by tumour cells is shown. Male C57 were injected with  $10^6$  B16F10 murine melanoma cells subcutaneously with either doxorubicin hydrochloride or dextrin- succinyl-

(6)

doxorubicin (34 mol % succinylation, 11.8% doxorubicin) at 5mg/kg doxorubicin equivalence into the intraperitoneal cavity (i.p.).

The mice were then culled after 2, 5, and 30 mins and after 1, 2, 5, 24, and 48 hours.

5 Tumours were removed and weighed. The tumour was then homogenised and doxorubicin extracted and quantified by HPLC for total doxorubicin present, Figure 3.

10 Figure 3 shows there is approximately a three fold increase in tumour levels of doxorubicin were found for the conjugate for all time intervals from 2 min up to 24 hours. After this period, there is no difference between conjugate or the free drug. The elevated levels of the conjugate were at their highest 5 min after injection.

#### *Example 4*

15

In this example the pharmacology of succinylated dextrin doxorubicin is determined and is presented in Table 2. Twenty four C57 black mice were injected subcutaneously (s.c.) with  $10^5$  B16F10 murine melanoma cells as described above and then monitored daily for well-being and the presence of palpable tumours. When 20 the tumours were palpable, mice were randomly assigned into groups of six and their tumours measured with a micrometer gauge. Tumour size and mouse body weight is recorded. Each group is then injected intra-peritoneally with either sterile saline (negative control), free doxorubicin ( $5\text{mg kg}^{-1}$ ) in sterile saline or dextrin-doxorubicin (11.8 wt%, 34% succinylation) at either  $5\text{mg kg}^{-1}$  or  $10\text{mg kg}^{-1}$ , on days 25 0, 1 and 2. The mice were monitored daily and tumour size and body weight recorded. Once the tumour area exceeded  $2.89 \text{ cm}^2$  the mice were culled according to UKCCCR guidelines. Mouse survival is then expressed as % T/C ( test/control saline).

30 The animals treated with doxorubicin ( $5\text{mg kg}^{-1}$ ) displayed a drop in body weight consistent with toxicity. However all mice tolerated the dextrin -doxorubicin conjugate at both doses. The higher dose ( $10\text{mg kg}^{-1}$ ) equates to approximately 2 mg

22-12-99 14:07

+44 1130 4702

22-DEC-1999 14:37

FROM GARRISON GODDARD FOOTE

P.12

R-119 Job-893

TO

01633814444

P.12

(1)

of conjugate. As shown in Table 2, dextrin- doxorubicin conjugate resulted in a T/C of approximately 140% indicating anticancer activity. In contrast, free doxorubicin was not active in this experiment.

5

10

15

22-12-99 14:07

+44 113 230 4702

P.13

R-119 Job-53

22-DEC-1999 14:37 FROM MERRISON GODDARD FOOTE

TO

01633814444


P.13

**Table 2**

Compound	Dose mg/kg (day 0,1,2)	Days survival after treatment (mean $\pm$ S.D.)	T/C (%)	Toxic deaths
Control (saline)	-	4.3 $\pm$ 0.5	100	0/6
Doxorubicin	5	4.5 $\pm$ 0.5 **	103	0/6
Dextrin-Dox	5	6.2 $\pm$ 0.8*	142	0/6
Dextrin-Dox	10	6.0 $\pm$ 1.1**	138	0/6

n=6 ns= not significant \*p=0.0004 \*\* p=0.005

Degradation of Dextrins of different degrees of modification by  $\alpha$ -Amylase



- Dextrin degradation by amylase is dependent on the degree of backbone succinylation. The dextrin-dox conjugate is rapidly degraded to oligomers




Figure 2

## Peak mass relative to pulullan




Figure 2. Degradation profiles of various succinylated dextrans showing the degradation of 34% succinylated dex-dox conjugate extended over 1 week at 37°C



Figure 3




Figure 3. Pharmacokinetic profile of doxorubicin and dextrin-doxorubicin. Data shown is mean  $\pm$  SE, n=3.

PAGE ONE  
23M4 Ref 92-6-2000  
Harrison Goddard Foote

**THIS PAGE BLANK (USPTO)**